and by periods of of our results XXXX Part the of Ib/IIa X BXXXX. the fourth our The most to proved everyone. highlighted of quarter be study morning, Phase from of positive company, one exciting significant Good
our foot the major we candidate, with also clinical of the affiliates including acquisition, the diabetic this fund Phase placement a March, APT existing with of in this led million transformational Deerfield e osteomyelitis.
In participation the adding treatment in Soon product BXXXX, announced and we investors, for the private acquisition pipeline additional milestones, to raised second connection achieving Action $XX after of of AMR II by Management, new Orbimed, in to funding next multiple sufficient third XXXX the these deeply institutional X readouts milestones data from and Capital. of quarter We the Foundation, respectively. reach support the Including of expected Fibrosis and quarter capital, have expects and from net appreciate BXXXX, investors. years, widely over the BiomX and clinical for to value Cystic BXXXX including financing respected our existing now Nantahala proceeds first and XXXX,
XX approximately and company leading standard testing. of disease further X The includes each with the cases, of one combined into which advance the with care therapeutics, programs the compassionate respective developing pipelines advance depth the clinical having phage expertise affairs With use a clinical area. in products, potential acquisition to most phage-based the the advanced created in of of extraordinary to phage company phage clinical products experience studies these possesses pivotal regulatory an help along multiple in INDs,
which, As X could the in anticipated has drive noted, potentially Phase company value stockholders. XXXX if combined readouts II for significant significant successful,
targeted and XXXX. already the surpassed on time remain week treatment track to has in on of study enrollment, results the Phase to quarter new foot focusing of in more we The I our study. our or osteomyelitis would and report clinical spend like first diabetic program II DFO, XX% today our XX ongoing
the When the wounds. heal blood a a from complication caused wounded are poor its flow to limited there blood body circulation, to area, in by with combination patients susceptibility to of high blood damage infection levels. and diabetes Ulcers nerve sugar struggles is
into the condition amputation. deepens ulcer So which limb could Once it is spreads lower as ulcers. is to a diabetic classified to serious that extent into bone, lead very these the condition the infected develop that wounds DFO, the
to includes offloading to fail oral of the amputations, the a in upon amputations leading surgery therapy. the of of care or of depending from IV to more of Unfortunately, infected standard the of cases foot, or toe DFO bone below cases or loss pressure the XX% above a loss the ankle. location often result antibiotic often in DFO limb course X-week XX% debridement severe in a of topical up
amputations remains limb the a this caused a With unmet are alone, number Control U.S. of in of and high of DFO XXX,XXX of need. Disease annually by approximately according which an staggering XX% in the area patients Center literature lower diabetic to
One antibiotic from a infecting polysaccharide these of creates barrier bacteria Biofilm, the of delivery mesh the to bone. inhibits poor is a the main reasons antibiotic suffer poor effectiveness by ulcer therapy a and in infected bone already patients for as secreted circulation. that the penetration who therapy limited blood
of effectiveness Beyond resistance to factor an contributing antibiotic delivery antibiotic is the treatment. limited additional
infections properly bacterial to aureus according MRSA, effectively to capacity break the target aureus. address Phage have example, potential strains phage has for are and drivers kill selected Staphylococcus failure. Staphylococcus XX% of treatment Methicillin-resistant and approximately When literature key therapy down For to the biofilm. a these antibiotic-resistant
were biofilm who when have multiple activity example, catalytic components. patients of the For Staphylococcal under against patients treatment our for sequenced selected current study domains of found were DFO to
therapeutic of to the as to scientific phage compassionate which biopsied the phage a in the from healing that and reported of positive are avoiding in literature developed outcomes approach technology wound pair one therapy optimally Moreover, resulted phage is outcome XX cases strains specific the on APT's its platform approach, using DFO of patient. main cases Out world treatment amputation. improve therapy. individualized BXXXX largest under in in banks phage from is based to supports of XX results bacteria the positive factor personalized utilizes numerous
to arsenal factors. pathogenic rapid aureus, The most compromising the virulence considered due its cases which bacterial time considered Staphylococcus in common bacteria DFO, in of approximately treatment the is infection targets, is doubling XX% and most of
billion represents $X BXXXX over $X a of in We opportunity and U.S. worldwide. the estimate billion commercial that
a BXXXX We placebo-controlled subjects to in are Phase randomized multicenter randomized with now DFO aureus. efficacy be planned a associated the XX and with study, are conducting investigating Approximately of safety, double-blind subjects II Staph to or tolerability and at placebo week administered placebo. route by XX. topical BXXXX route X and at is BXXXX topical the at by of X X:X IV to or weekly weeks ratio only each
appropriate. Over of the subjects treatment in the period, includes all with antibiotic care, treated to accordance XX-week continue standard as be which
track of the the week As of first the quarter XX, in evaluating we patients osteomyelitis results report to study, the are amounts associated XXXX. XX XX% with in of enrolled enrollment, and which have now, to at on of wound healing over target
We second osteomyelitis of then is assessment rates in planned on XXXX, expect CF CRP fibrosis report in XXXX, at to the biomarkers for resolution of Type clinical development BXXXX. week the hold to a expect quarter XX. our of established readout the in to we or such program amputation C clinical ESR discuss plan X-ray cystic a and meeting based with second as to and With first respect evaluate quarter which FDA to
Phase all a intend the following CMC begin submit and FDA work, and we to alignment Assuming completion enrollment of regulatory approval IIb relevant authorities in to patient the protocol our study. with
the quarter this line study As XXXX. from already in noted, of estimate we results third releasing top
full I'll year XXXX quarter pass Avi results. over to And financial now review to it our and fourth
